Efficacy and Safety of Intravenous Colistin in Preterm Infants with Nosocomial Sepsis Caused by Acinetobacter baumannii

Abstract

Objectives To describe the efficacy of intravenous colistin on clinical and microbiological outcomes in preterm infants with nosocomial sepsis in neonatal intensive care unit (NICU) and define adverse events observed with this treatment.

Methods The records of preterm infants who received colistin with or without positive cultures in the NICU were retrospectively reviewed. Patients were evaluated for response to therapy and side effects.

Results A total of 21 preterm infants with medians of 28 weeks (23–36) gestational age and 870 g (620–2,650) birth weight were included. The median duration and dose of colistin therapy were 9 days (3–26) and 3 mg/kg/d (2–5). Recovery rate in patients including all with/without positive culture was 81% (17/21). Microbiological clearance by colistin was 69% (9/13). The major side effect observed was acute kidney injury (19%). At least 24% of infants required electrolyte supplementation during the colistin therapy. Magnesium levels were significantly lower at the end of the colistin therapy (p < 0.001). Acute kidney injury and electrolyte disturbances including hypomagnesemia were reversible in all surviving patients.

Conclusion We suggest that renal function tests and serum electrolytes should be monitored closely and replaced in case of any need during the colistin therapy in preterm infants.

Keywords

Acinetobacter baumannii - colistin - neonatal intensive care unit - nosocomial infection - preterm

• References

• 1 Isturiz R. Global resistance trends and the potential impact on empirical therapy. Int J Antimicrob Agents 2008; 32 (Suppl. 04) S201-S206
• 2 Giske CG, Monnet DL, Cars O, Carmeli Y ; ReAct-Action on Antibiotic Resistance. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008; 52 (3) 813-821
• 3 Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis 2009; 22 (6) 535-543
• 4 Berlana D, Llop JM, Fort E, Badia MB, Jódar R. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health Syst Pharm 2005; 62 (1) 39-47
• 5 Tamma PD, Newland JG, Pannaraj PS , et al. The use of intravenous colistin among children in the United States: results from a multicenter, case series. Pediatr Infect Dis J 2013; 32 (1) 17-22
• 6 Iosifidis E, Antachopoulos C, Ioannidou M , et al. Colistin administration to pediatric and neonatal patients. Eur J Pediatr 2010; 169 (7) 867-874
• 7 Jajoo M, Kumar V, Jain M, Kumari S, Manchanda V. Intravenous colistin administration in neonates. Pediatr Infect Dis J 2011; 30 (3) 218-221
• 8 Falagas ME, Vouloumanou EK, Rafailidis PI. Systemic colistin use in children without cystic fibrosis: a systematic review of the literature. Int J Antimicrob Agents 2009; 33 (6) e1 , e13
• 9 Gounden R, Bamford C, van Zyl-Smit R, Cohen K, Maartens G. Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections. BMC Infect Dis 2009; 9: 26
• 10 Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36 (5) 309-332
• 11 Mehta RL, Kellum JA, Shah SV , et al; Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11 (2) R31
• 12 Cakir U, Alan S, Zeybek C , et al. Acquired bartter-like syndrome associated with colistin use in a preterm infant. Ren Fail 2013; 35 (3) 411-413
• 13 Celebi S, Hacımustafaoglu M, Koksal N, Ozkan H, Cetinkaya M. Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients. Pediatr Int 2010; 52 (3) 410-414
• 14 Rosanova M, Epelbaum C, Noman A , et al. Use of colistin in a pediatric burn unit in Argentina. J Burn Care Res 2009; 30 (4) 612-615
• 15 Kapoor K, Jajoo M, Dublish S, Dabas V, Gupta S, Manchanda V. Intravenous colistin for multidrug-resistant gram-negative infections in critically ill pediatric patients. Pediatr Crit Care Med 2013; 14 (6) e268-e272
• 16 Celik IH, Demirel G, Tatar Aksoy H , et al. Acinetobacter baumannii: an important pathogen with multidrug resistance in newborns [in Turkish]. Mikrobiyol Bul 2011; 45 (4) 716-722
• 17 Bergen PJ, Li J, Nation RL. Dosing of colistin-back to basic PK/PD. Curr Opin Pharmacol 2011; 11 (5) 464-469
• 18 Garonzik SM, Li J, Thamlikitkul V , et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55 (7) 3284-3294
• 19 Markou N, Markantonis SL, Dimitrakis E , et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 2008; 30 (1) 143-151
• 20 Daikos GL, Skiada A, Pavleas J , et al. Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use. J Chemother 2010; 22 (3) 175-178
• 21 Plachouras D, Karvanen M, Friberg LE , et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53 (8) 3430-3436
• 22 Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 2008; 14 (9) 816-827
• 23 Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents 2010; 35 (3) 297-300
• 24 Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006; 10 (1) R27
• 25 Falagas ME, Sideri G, Vouloumanou EK, Papadatos JH, Kafetzis DA. Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis. Pediatr Infect Dis J 2009; 28 (2) 123-127
• 26 Lewis JR, Lewis SA. Colistin interactions with the mammalian urothelium. Am J Physiol Cell Physiol 2004; 286 (4) C913-C922
• 27 Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honoré PM. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care 2011; 1 (1) 14